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Abstract. The human P2X7 receptor is significant and exhibits 
several functions in neoplasia. At present, little is known with 
regard to its regulation. P2X7 expression may be regulated 
post‑transcriptionally and putative microRNA (miRNA) binding 
sites are considered to be involved. The aim of this study was 
to determine whether miRNAs (miR‑21, let‑7 g and miR‑205) 
regulate P2X7 mRNA stability. In addition, the impact of P2X7 
expression in patients with non‑small cell lung cancer (NSCLC) 
was investigated. P2X7 mRNA and mature Let‑7 g, miR‑21, 
and miR‑205 expression levels were quantified in 96 NSCLC 
cases using quantitative reverse transcription polymerase chain 
reaction. In all samples, epidermal growth factor receptor 
and K‑Ras mutational analysis was also performed. Samples 
with low P2X7 expression were found to exhibit a higher fold 
change in miR‑21 expression when compared with samples 
exhibiting high P2X7 expression. Significantly higher miR‑21 
expression was observed in the tumors of NSCLC patients 
with a K‑Ras mutation when compared with patients who had 
K‑Ras wild‑type tumors (P=0.003). Additionally, to evaluate 
the association between P2X7 expression and prognosis in 
NSCLC patients, survival analysis was performed using the 
Kaplan‑Meier method. A significant difference in the progres-
sion‑free survival and overall survival in the NSCLC patients 
with high P2X7 expression was identified, when compared with 
that of patients with low expression (P=0.03 and P=0.02, respe-
tively). Therefore, we hypothesized that high levels of miR‑21 
expression in NSCLC patients with K‑Ras mutations may be 
regulated by a complex circuit, including P2X7 downregulation 
and together these processes may promote tumor progression.
Introduction
The human P2X7 receptor is a trimeric ligand‑gated cation 
channel encoded by the P2RX7 gene, which is located on 
chromosome 12q24 (1). P2X7 is expressed in a wide variety 
of normal and disease‑associated cell types. Activation of this 
receptor by extracellular adenosine 5'‑triphosphate results in 
numerous downstream events, including the release of proin-
flammatory mediators, cell proliferation or death, and killing 
of intracellular pathogens. As a result, P2X7 is significant and 
exhibits several functions in neoplasia. P2X7 and its regula-
tion is of considerable interest with regard to human health 
and disease, including in the development and publication of a 
number of patents (2). At present, little is known with regard to 
how epithelial cells regulate expression of the P2X7 receptor. 
However, a preliminary study revealed that P2X7 expression 
is also regulated post‑transcriptionally (3). In addition, putative 
microRNA (miRNA) binding sites within the P2RX7 3'‑untrans-
lated region (UTR) have also been identified (4,5). miRNAs are 
small, noncoding 18‑25‑nucleotide RNAs that regulate mRNA 
targets and control critical functions in a variety of biological 
processes (6). Animal miRNAs form imperfectly base‑paired 
duplexes with miRNA response elements in target mRNAs. 
This interaction may inhibit translation and lead to degradation 
of mRNA (7,8). For effective repression, base‑pairing between 
the miRNA‑response elements and the first 2‑7 nucleotides of 
the miRNA, referred to as the 'seed' region, is important (9‑11). 
miR‑21 is overexpressed in numerous types of tumors, including 
non‑small cell lung cancer (NSCLC), indicating its significance 
in cancer development. However, the underlying mechanism of 
miR‑21‑mediated tumorigenesis remains unclear, largely due 
to limited knowledge with regard to miR‑21 targets. Various 
computer‑aided algorithms have predicted a number of putative 
miR‑21 targets, however, these targets have not been validated 
experimentally. The aim of this study was to investigate whether 
miRNAs (miR‑21, let‑7 g, and miR‑205) regulate P2X7 mRNA 
stability and to evaluate the prognostic impact of P2RX7 expres-
sion in patients with NSCLC.
Materials and methods
Patients. In total, 96 NSCLC patients were retrospectively 
selected from patients who had undergone resection at the Unit of 
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Thoracic Surgery of Pisa, Azienda Ospedaliero‑Universitaria 
Pisana (Pisa, Italy) between 1993 and 2012. Histological 
diagnoses were formulated according to the World Health 
Organization classification (12,13). Clinicopathological char-
acteristics were collected in 82 cases, while survival data 
were obtained for 53 patients. All patients provided written 
informed consent prior to the molecular analyses. This study 
was approved by the ethics committee of the University of 
Pisa (Pisa, Italy).
RNA and DNA isolation. RNA and DNA were isolated from 
5‑10 µm sections of 82 formalin‑fixed paraffin‑embedded 
(FFPE) tissues and 14 cytological specimens. The cyto-
logical samples were obtained from bronchial brushing, 
aspirative transbronchial needle aspiration and transtho-
racic needle aspiration. The cyctolgical preparations were 
conducted according to a standard specimen processing 
procedure in our laboratory. All samples were fixed in 
Cytofix (BD Biosciences, San Jose, CA, USA) and stained 
with Papanicolaou for 20 min in an automated stainer (Leica 
Stainer; ST5020, Leica, Mannheim, Germany). For aspirative 
cytology (transbronchial needle aspiration and transthoracic 
needle aspiration), the specimens were fixed in Cytofix and 
stained with Papanicolaou staining (Kaltek s.r.l., Padua, 
Italy). Bronchial brushing samples and cellular material were 
centrifuged (Sorvall T6000D, Thermo Scientific, Rockford, 
IL, USA) at 1366 x g for 10 min. Next, 10% neutral buff-
ered formalin (Diapath S.p.A., Bergamo, Italy) was added 
to the pellet and the pellet placed into a tissue processing 
and embedding cassette (Bio Optica S.p.A., Milan, Italy) and 
embedded with paraffin.
P2X7, miRNA expression and mutational analysis. 
Quantification of mRNA expression was performed in 
triplicate using quantitative reverse transcription poly-
merase chain reaction (PCR) with the following primers: 
Forward, 5'‑CTCCCATCTCAACTCCCTGA‑3' and reverse, 
5'ACCAGCTTCCTGAACAGCTC‑3', for P2X7. Specific 
TaqMan® miRNA Assays (Applied Biosystems Life 
Technologies, Foster City, CA, USA) were used for Let‑7 g, 
miR‑21, miR‑205 and RNU6B according to the manufac-
turer's instructions. The threshold cycle (Ct) and baselines 
were determined using manual settings, where Ct was set 
in the linear phase of the amplification and baseline in the 
initial cycles of PCR. Expression was calculated by relative 
quantification and fold expression changes were determined 
by the 2‑ΔΔCT method using the DataAssist software (Applied 
Biosystems Life Technologies).
Mutational analysis was also performed for all samples. 
The mutational status of the codons 12‑13 of the K‑Ras gene 
was analyzed by pyrosequencing using the anti‑epidermal 
growth factor receptor (EGFR) MoAb response® kit (K‑Ras 
status) (Diatech Pharmacogenetics, Jesi, Italy) according to 
the manufacturer's instructions.
PCR‑single stranded conformation polymorphism and 
sequencing analysis were used for EGFR genotyping in 
exons 18‑21, as previously described (14).
Statistical analysis. One‑way analysis of variance and χ2 
tests were used to determine the association between miRNA 
expression, P2X7 mRNA expression and the different 
parameters. The survival analysis was performed using the 
Kaplan‑Meier method. Statistical analyses were performed 
using the JMP10 software (SAS, Cary, NC, USA) and a 
two‑tailed P<0.05 was considered to indicate a statistically 
significant difference.
Results
Patient characteristics. This study was conducted in 
96 patients with NSCLC, which included 63 adenocar-
cinomas, 31 squamous cell carcinomas and two large cell 
carcinomas. The median age at diagnosis was 66.5 years 
(range, 46‑83 years). Using the TNM staging system, the 
distribution of the patients was as follows: 18 cases, stage I; 
44 cases, stage II; 14 cases, stage III; and six cases, stage IV; 
34 cases, negative lymph node status; 20 cases, N1 status; 
23 cases, N2 status; and five cases, Nx status (13).
Survival data were obtained for 53 patients (median 
follow‑up duration, 36 months; range, 7‑98 months). Disease 
progression and mortality from lung cancer were observed in 
32 (60.3%) and 18 (34%) of the 53 NSCLC patients, respec-
tively. The median progression‑free survival (PFS) and 
overall survival (OS) were 18 months (95% CI, 2‑89 months) 
and 25 months (95% CI, 2‑90 months), respectively.
P2X7 and miRNA expression and clinicopathological 
characteristics. P2X7 mRNA expression was quantified and 
normalized to the glyceraldehyde 3‑phosphate‑dehydroge-
nase housekeeping gene. The expression of mature Let‑7 g, 
miR‑21, and miR‑205 was quantified and normalized to the 
RNU6B endogenous control in 96 NSCLC tissues using 
quantitative PCR. The samples were divided into high and 
low expression groups based on the median fold change 
values (0.56, P2X7; 1.02, Let‑7 g; 5.81, miR‑21; and 0.01, 
miR‑205). No statistically significant associations were 
identified between P2X7 mRNA levels and the main clinico-
pathological characteristics of the NSCLC patients (Table I). 
With regard to the association between P2X7 expression 
levels and the miRNA profile, it was found that samples with 
low P2X7 expression exhibited a higher miR‑21 fold change 
(11.42±2.28) when compared with samples expressing high 
levels of P2X7 (7.41±2.28). In addition, the mutational anal-
ysis revealed K‑Ras and EGFR mutations in 19.7 and 23.9% 
of the NSCLC patients, respectively. K‑Ras and EGFR muta-
tions were mutually exclusive (P=0.0006), observed only in 
the NSCLC patients with adenocarcinoma (P<0.0001). The 
mutations were associated with female gender (P<0.0001) 
and patients that did not smoke (P<0.0001). Notably, signifi-
cantly higher miR‑21 expression was observed in the NSCLC 
tumors that expressed mutant K‑Ras when compared to that 
of tumors that expressed wild‑type K‑Ras (P=0.003). In addi-
tion, the majority of the tumors that expressed mutant K‑Ras 
exhibited low P2X7 expression.
Survival analysis. To evaluate the association between P2X7 
expression and the prognosis of NSCLC patients, a survival 
analysis using the Kaplan‑Meier method was conducted. In 
this analysis, disease recurrence and overall postoperative 
survival were used as endpoints.
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A significant difference was identified between the PFS 
(P=0.03) and OS (P=0.02) of the NSCLC patients with high 
P2X7 expression and the patients with low P2X7 expression 
(Fig. 1).
Discussion
P2X7 is characterized by high plasticity, as its expression 
is modulated in a cell type‑ or differentiation‑dependent 
manner (15). Transcriptional mechanisms may underlie the 
increased P2X7 expression observed in lung cancer, and the 
expression of individual isoforms of the same protein may or 
may not correlate with the mRNA, indicating that separate 
post‑translational mechanisms may account for the regulation 
of P2X7 expression (2). In the current study, P2X7 mRNA 
levels were evaluated and quantified by quantitative PCR in 
NSCLC cases. One of the aims of this study was to explore 
whether particular miRNAs (miR‑21, let‑7 g and miR‑205) 
are important for P2X7 mRNA regulation. Samples with low 
P2X7 expression were found to exhibit a higher miR‑21 fold 
change when compared with samples exhibiting high levels 
of P2X7 expression. In animals, miRNAs are hypothesized to 
bind via a partially homologous sequence in the target gene at 
the 3'‑UTR, causing translational repression (6). With regard to 
oncogenic miRNAs, a limited number of target genes have been 
characterized experimentally, however, increasing evidence 
indicates putative targets, predicted by different algorithm 
programs. For example, the Sanger miRNA database target 
Figure 1. Kaplan‑Meier curves for survival analysis of (A) PFS and (B) OS 
in non‑small cell lung cancer patients with different P2X7 mRNA expression 
levels. P=0.03, log‑Rank test for PFS; P=0.02, log‑Rank test for OS. PFS, 
progression free survival; OS, overall survival.
Table I. Correlations between P2X7 mRNA expression and the main clinicopathological characteristics of the non‑small cell lung 
cancer patients.
 P2X7 mRNA expression, n (%)
 -------------------------------------------------------------------------------------
Parameter Low High P-value
Age, years
  ≤68 28 (56) 22 (44) 0.21
  >68    20 (43.5)    26 (56.5)
Gender, n
  Male    33 (45.8)    39 (54.2) 0.15
  Female    15 (62.5)      9 (37.5)
Histology, n
  ADC    32 (50.8)    31 (49.2) 0.21
  SCC    14 (45.2)    17 (54.8)
  LCC     2 (100) 0 (0)
Tumor stagea, n
  T1 (T1a‑T1b)      6 (46.1)      7 (53.9) 0.70
  T2 (T2a‑T2b) 25 (51) 24 (49)
  T3‑T4   8 (40) 12 (60)
Lymph‑node status, n
  Negative    21 (61.8)    13 (38.2) 0.09
  Positive    16 (37.2)    27 (62.8)
  Nx   2 (40)   3 (60)
aTNM staging system. ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma.
  A
  B
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search (www.mirbase.org.) reveals >900 targets for miR‑21, 
which is not consistent with the prediction of ~100 target 
genes per single miRNA (16). Therefore, it is likely that only 
a small fraction of predicted targets may be true targets and 
thus, it would be difficult to validate them. In the present 
study, an exact putative target site was not identified for 
miR‑21 within the 3'‑UTR (1272 nucleotides) of the human 
P2X7 gene (NM_002562). However, at the 499 nucleotide 
position, a partial target site (3'‑GAAT‑5') was identified 
for the miR‑21 seed sequence (5'‑AGCUUA‑3'). Further 
studies are required to investigate whether P2X7 is a target 
of miR‑21, considering that in animals, the miRNA does 
not bind to its target as efficiently as in plants. Furthermore, 
polymorphisms in the miRNA 'seed region' (5) or in their 
binding sites in target genes have been identified and appear 
to be involved in cancer (17).
Furthermore, significantly higher miR‑21 expression was 
observed in NSCLC patients with K‑Ras‑mutated tumors, 
when compared with K‑Ras wild‑type specimens, according 
to our previous study (18). High levels of miR‑21 expression 
in NSCLC patients harboring K‑Ras mutations may indicate a 
synergistic assocation between miR‑21 and K‑Ras oncogenes, 
including P2X7 downregulation. Taken together, it is likely 
that these processes promote tumor progression. The second 
aim of the study was to evaluate the putative prognostic 
role for P2X7 expression, as this role remains controver-
sial. Based on previous studies, it appears that low levels of 
P2X7 activation facilitates the growth or survival of certain 
tumor cell types (19). However, at high levels, the extracel-
lular receptor promotes cell death (20). Previous reports have 
linked increased P2X7 expression with a poor prognosis in 
several types of leukemia (21,22) and solid tumors (23‑25). 
By contrast, Souza et al (26) revealed that extracellular ATP 
effectively inhibited proliferation and induced apoptosis or 
necrosis of tumor cells (26). These studies also demonstrated 
that the brief exposure of tumor cells to ATP was able to 
efficiently induce cell death (reduction of cell growth and 
induction of autophagy), which was largely mediated via 
P2X7, indicating the anti‑tumor potential of purine‑based 
drugs (27). The results of the current study are consistent 
with those found by Souza et al (26), showing that defec-
tive P2X7 expression, as a result of miR‑21 activation by a 
K‑Ras mutation, may lead to reduced tumor‑killing activity, 
resulting in a poorer prognosis. The identification of putative 
associations of P2X7 with biological behavior in NSCLC 
would be of considerable interest, and further studies will aid 
in the understanding of P2X7 gene regulation and its role in 
lung cancer. The significant differences in clinical outcome of 
NSCLC patients with high P2X7 expression identified in this 
study indicate that expression of the P2X7 receptor may be a 
useful prognostic marker, as well as a novel target for therapy. 
Further studies, including the investigation of P2X7 regulation 
by various micro‑RNA or other epigenetic mechanisms, may 
provide more insight with regard to the results of this study.
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